Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
Status:
Terminated
Trial end date:
2018-06-07
Target enrollment:
Participant gender:
Summary
By combining a variety of agents that potentiate Zidovudine (ZDV), the investigators hope to
induce remission in this generally fatal disease. Most therapies for aggressive B cell
lymphomas are based upon intensive chemotherapeutic regimens, expensive modalities (bone
marrow transplant, Rituximab), or experimental approaches (gene therapy, cytotoxic T cell
infusion) that are difficult to implement in heavily pre-treated patients. Therapy for
relapsed aggressive B cell lymphomas is very poor. Even curable lymphomas such as Burkitt
Lymphoma (BL) and Hodgkin lymphoma are extremely difficult to treat in relapse and/or after
stem cell transplant failure. The investigators propose a novel therapeutic approach that
exploits the presence of Epstein-Barr virus (EBV) in lymphomas; antiviral mediated
suppression of NF-kB and disruption of viral latency.